Tarvacin, are you aware that there are dozens of Big Pharma that need a cancer immunotherapy pipeline? PS Targeting "will" play one hell of a major role as a global upstream checkpoint, as it exists on every stressed and cancer cell, unlike Anti-TIM.
More importantly, do you realize that Anti-TIM "DOES NOT" reduce side effects of downstream drugs that its combined with? I wonder why????
PS Targeting Bavituximab reduces side effects if its combined with downstreamers, such as Yervoy.
You should keep an eye on the Bavi+Yervoy results and pay attention to the Notch Signaling Conference over on Mykonos in Greece as Dr. Dmitry Gabrilovich may have some interesting words that will help those in deciding which checkpoint inhibitor works best---
the down-dreamers or the only global, upstream checkpoint inhibitor in PS Targeting agents, such as Bavituximab.
The bottom line is that Notch Signaling is changed, providing the best optimal immune response, when there is a decrease in MDSC's .... which all occurs when flipped-PS is blocked/targeted by a PS Targeting agent such as with Bavituximab.
IF another Big Pharma would like to use another method, such as only with Anti-TIM (without a PS Targeting agent) then good luck to them .... there are dozens of other Big Pharmas that would surely like that match up if they have Bavituximab on their side.
News 
Market Data 
Discover 
